Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Roche's Gazyva/Gazyvaro Meets Primary Endpoint In Phase III INShore Study For Children And Young Adults With Idiopathic Nephrotic Syndrome

Author: Benzinga Newsdesk | October 28, 2025 01:15am
  • Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 
  • If approved, Gazyva/Gazyvaro could help children and young adults sustain remission, potentially with a reduced need for steroids to manage their disease1
  • INShore is the first global phase III study of a targeted therapy in this chronic kidney disease commonly diagnosed in early childhood

Posted In: RHHBF RHHBY RHHVF


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist